The making of biotechnology: a case study of radical innovation

This study examines decision making in large and small firms undertaking biotechnology innovation and identifies factors influencing innovation. It also considers aspects of environments external to firms, but relevant to the process of innovation. The study suggests that innovation is best understood as process of change both within the firm and in the external environment. Factors internal to firms influencing key decisions included economic and political evaluations, company culture, organization, and in large firms, previous areas of corporate activity. A scarcity of appropriate knowledge relating to technical and non-technical aspects of innovation acted as severe restraints to Dedicated Biotechnology Firms (DBFs). Factors external to firms shaping decisions about the technology included changes in the socio-economic and political environment, risk regulation and patenting. Lack of funding and difficulties associated with venture capital constituted additional hurdles for DBFs. The findings of the study highlight a series of erroneous assumptions built into the linear model of innovation. The cumulative nature of innovation and the importance of 'learning by doing' constitute elements of the critique of the linear model. For related reasons, some Post Fordist theories of current change in advanced industrialized countries, particularly those which advocate flexible specialization as a new model for industrial growth also prove problematic

The republic of science meets the republics of somewhere: embedding scientific excellence in sub-Saharan Africa

How can international and regional actors on the one hand, and national actors on the other hand, align and realign practice, funding and support to ensure embedded excellence in science and research in sub-Saharan Africa (SSA)? What are the roles, challenges, and opportunities for science granting councils (SGCs) – science or research councils, or agencies responsible for the funding and/or management of science and research in SSA – in embedding scientific excellence in SSA? In this chapter, we examine the notion of embeddedness, or relevance, of scientific excellence to national development agenda. We discuss actions that SGCs can take to foster and support embedded excellence in science and research in SSA. We argue that the notion of excellence needs to extend beyond the traditional metrics, such as publications and citations, if science and research are to be relevant to national contexts. We maintain that in order to embed scientific excellence in SSA, adequate alignment and realignment of the various agenda (of international, regional and national actors), practice, funding and support for science and research in Africa will be necessary. To achieve this goal, SGCs in SSA will require greater ownership of their research agenda, autonomy, resource, vision and alliances. Grounding the ‘Republic of Science’ in the realities of national contexts will require this. Furthermore, a set of ‘capitals’, strengthened capabilities, and capacities will be needed to support the process of embedding excellence at the national level.Published by African Minds

Issues in the political economy of agricultural biotechnology

Agricultural biotechnology is typically analyzed critically by means of a political ecological focus on the science and its ecological implications - agbio science as a radical, and 'non-natural', break with 'normal' trajectories for 'new plant science'. Surprisingly, less attention has been paid to a range of key political economic issues, many of which were important in the last big food production technology 'revolution', the Green Revolution. This paper will focus on three areas of political economy. First, we discuss the corporate drivers of agricultural biotechnology, and examine whether these drivers have already set the technology so that it cannot be changed. Second, we investigate the present economics and technology of genetic modification in plants, and its possible future. Third, we examine empirical evidence for alternative visions of the technology

OECD International Futures Project on “The Bioeconomy to 2030: Designing a Policy Agenda”. Health Biotechnology to 2030

This is a report commissioned by the OECD. Innogen was asked to write a scenario report for the OECD International Futures Programme to consider the pathways that health biotechnologies could follow, the future trajectory of the bio-economy primarily in the context of human health and the likely societal, economic and policy impacts of these projected outcomes, focusing on the period 2015 to 2030 . We chose as a starting point a world health care system that, from the perspective of potential impacts of biotechnology, has been mainly under the influence of the innovation model of the multinational drug companies. To date the scope and inventiveness of this model has been constrained by the expensive and lengthy regulatory systems that act as a barrier to entry for small companies that could challenge the industry status quo and our report focuses on the need for regulatory change as a prelude to the emergence of a new, more radically innovative, health care sector. In the absence of such change our scenario predicts a health care sector that is increasingly populated by pharmaceutical commodity producers, research and development focused on incremental, piecemeal change, lack of both public and private sector funding, dysfunctional competition within and between companies and adversarial relationships with regulators. A radical change scenario on the other hand “Networked Health Care” would depend on regulatory agencies collaborating, as an integral component of the innovation system, in the proactive development of new, smarter regulatory approaches to the generation of benefits based on fundamental discoveries in life sciences. Our report describes the pre-conditions needed to lead to the more positive scenario and the roles of key actors in promoting or resisting such changes

Regulamentação dos riscos e estratégias das empresas em biotecnologia

This paper discusses strategic decision making in firms pursuing biotechnology innovation and the influence of risk regulation on firm strategy. Data from three research projetcs, involving interviews with over 60 managers from agricultural and food related biotechnology companies and also over 60 key participants in the regulatory process in the UK and EC, shows a diversity of strategy and opinion. While some industry representatives identified new risk regulations governing the release of genetically manipulated organims (GOMs) as the primary constraint on biotecnology innovation, the findings of the study painted a more complex picture. The controversies surrounding the issue of risk regulation and its impact on innovation are best understood if viewed in the context of other political and economic factors. We conclude that the actual impact of risk regulation on industry strategies is probably less than the rhetoric of industry lobbyists would suggest. At the same time, the very act of lobbying so forcefully could lead to a public backlash against industry that would be much more damaging than the regulation itself.This paper discusses strategic decision making in firms pursuing biotechnology innovation and the influence of risk regulation on firm strategy. Data from three research projetcs, involving interviews with over 60 managers from agricultural and food related biotechnology companies and also over 60 key participants in the regulatory process in the UK and EC, shows a diversity of strategy and opinion. While some industry representatives identified new risk regulations governing the release of genetically manipulated organims (GOMs) as the primary constraint on biotecnology innovation, the findings of the study painted a more complex picture. The controversies surrounding the issue of risk regulation and its impact on innovation are best understood if viewed in the context of other political and economic factors. We conclude that the actual impact of risk regulation on industry strategies is probably less than the rhetoric of industry lobbyists would suggest. At the same time, the very act of lobbying so forcefully could lead to a public backlash against industry that would be much more damaging than the regulation itself

STI policy and governance in Sub-Saharan Africa: fostering actors’ interactions in research and innovation

This study investigates science, technology, and innovation (STI) policy and governance in relation to research and innovation (R&I) ecosystems in Sub-Saharan Africa (SSA). To understand the implications of STI policy and governance on R&I, the authors focus on university, industry and government actors; using the Triple Helix and National Systems of Innovation approaches as analytical frameworks to guide the study. The authors identify a range of factors hindering R&I actors’ interactions, including gaps in STI governance responsibilities and accountabilities, policymaking and structural transitions, R&I management capacity and capability gaps. Based on the findings, they propose changes to policymaking and the governance of R&I in SSA, in addition to advancing innovative approaches such as ‘resource circulation’ in the context of knowledge, research and science infrastructure scarcity. The findings provide fresh insights into STI policy and governance frameworks, fostering actors’ interactions and supporting performance improvements in research, science and innovation systems across Africa

Below the Radar: What does Innovation in Emerging Economies have to offer other Low Income Economies?

Between 1970 and 2000 the proportion of global R&D occurring in low income economies rose from two percent to more than 20 percent. However, this rising commitment to R&D does not easily translate into the emergence of a family of innovations meeting the needs of low income consumers "at the bottom of the pyramid", since much of these technological resources are invested in outdated structures of innovation. A number of transnational corporations are targeting these markets but it is our contention that much of the previously dominant innovation value chains are either ignorant of the needs of consumers at the bottom of the pyramid, or lack the technologies and organisational structures to meet these needs effectively. Instead, the firms and value chains that are likely to be most successful in these dynamic new markets are those that are emerging in China and India and other developing countries, disrupting global corporate and locational hierarchies of innovation.Science and Technology, Asian drivers, Innovation Systems, Millennium Development Goals